Sporadic Medullary Thyroid Cancer

  • Nuh Zafer Cantürk
  • Sertaç Ata GülerEmail author
  • Turgay Şimşek


Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland. It accounts for approximately 1–2% of thyroid cancers. The production of calcitonin is a characteristic feature of this tumor. Most of the MTCs are sporadic whereas 25% of cases are familial as part of the multiple endocrine neoplasia type 2 (MEN2) syndrome. For sporadic MTCs, there are no germline RET mutations. The most common presentation of sporadic MTC is a solitary thyroid nodule. Systemic symptoms may occur due to hormonal secretion by the tumor. Most sporadic MTCs also secrete carcinoembryonic antigen (CEA). The diagnosis of sporadic MTC is usually made after fine needle aspiration (FNAB) biopsy in a patient who has a solitary thyroid nodule. Patients with sporadic MTC can be cured only by complete resection of the thyroid tumor with bilateral central neck lymph node dissection. For patients with the residual or recurrent disease after primary surgery or for those with distant metastases, the most appropriate treatment is less clear and still debatable.

In this case presentation, we discussed a patient with an MTC, its evaluation, diagnosis, management and the future of the MTC according to the literature.


Sporadic medullary thyroid cancer (MTC) Parafollicular or C cells Calcitonin Multiple endocrine neoplasia type 2 (MEN-2) Germline RET mutations Carcinoembryonic antigen (CEA) 


  1. 1.
    Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567.CrossRefGoogle Scholar
  2. 2.
    Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984;63:319.CrossRefGoogle Scholar
  3. 3.
    Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77:1556.CrossRefGoogle Scholar
  4. 4.
    Gagel RF, Hoff AO, Cote GJ. Medullary thyroid carcinoma. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 967.Google Scholar
  5. 5.
    Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139.CrossRefGoogle Scholar
  6. 6.
    Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:475.CrossRefGoogle Scholar
  7. 7.
    Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;31:1960.CrossRefGoogle Scholar
  8. 8.
    Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R, et al. Medullary thyroid microcarcinoma recommendations for treatment—a single-center experience. Surgery. 2007;142:1003.CrossRefGoogle Scholar
  9. 9.
    Machens A, Dralle H. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol. 2016;175:219.CrossRefGoogle Scholar
  10. 10.
    Kwon H, Kim WG, Sung TY, Jeon MJ, Song DE, Lee YM, et al. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma. J Surg Oncol. 2016;113:152.CrossRefGoogle Scholar
  11. 11.
    Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg. 2007;142:289.CrossRefGoogle Scholar
  12. 12.
    Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53:278.CrossRefGoogle Scholar
  13. 13.
    Trimboli P, Nasrollah N, Amendola S, Rossi F, Ramacciato G, Romanelli F, et al. Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer? Endocr J. 2012;59:503.CrossRefGoogle Scholar
  14. 14.
    Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol. 2005;91:56.CrossRefGoogle Scholar
  15. 15.
    Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist. 2011;16:49.CrossRefGoogle Scholar
  16. 16.
    Toledo SP, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo). 2009;64:699.CrossRefGoogle Scholar
  17. 17.
    Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med. 2005;142:926.CrossRefGoogle Scholar
  18. 18.
  19. 19.
    Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF, GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077.CrossRefGoogle Scholar
  20. 20.
    Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655.CrossRefGoogle Scholar
  21. 21.
    Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590.CrossRefGoogle Scholar
  22. 22.
    Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med. 2011;13:755.CrossRefGoogle Scholar
  23. 23.
    Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996;81:1619.PubMedGoogle Scholar
  24. 24.
    American Joint Committee on Cancer (AJCC). In: Edge SB, Byrd DR, Compton CC, et al., editors. Cancer staging manual. 7th ed. New York: Springer; 2010.CrossRefGoogle Scholar
  25. 25.
    Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 1999;230:697.CrossRefGoogle Scholar
  26. 26.
    Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1983;57:124.CrossRefGoogle Scholar
  27. 27.
    Engelbach M, Görges R, Forst T, Pfützner A, Dawood R, Heerdt S, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab. 2000;85:1890.PubMedGoogle Scholar
  28. 28.
    van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990;212:395.CrossRefGoogle Scholar
  29. 29.
    Modigliani E, Cohen R, Campos JM, Franc B, Niccoli-Sire P, Conte-Devolx B, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998;48:265.CrossRefGoogle Scholar
  30. 30.
    Ho AS, Wang L, Palmer FL, Yu C, Toset A, Patel S, et al. Postoperative nomogram for predicting cancer-specific mortality in medullary thyroid Cancer. Ann Surg Oncol. 2015;22:2700.CrossRefGoogle Scholar
  31. 31.
    Faggiano A, Talbot M, Lacroix L, Bidart JM, Baudin E, Schlumberger M, et al. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol (Oxf). 2002;57:813.CrossRefGoogle Scholar
  32. 32.
    Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54:657.CrossRefGoogle Scholar
  33. 33.
    Machens A, Hauptmann S, Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? J Clin Endocrinol Metab. 2008;93:2234.CrossRefGoogle Scholar
  34. 34.
    Walter MA, Meier C, Radimerski T, Iten F, Kränzlin M, Müller-Brand J, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer. 2010;116:31.PubMedGoogle Scholar
  35. 35.
    Azar FK, Lee SL, Rosen JE. Medullary thyroid cancer: an update for surgeons. Am Surg. 2015;81:1–8.PubMedGoogle Scholar
  36. 36.
    Skoura E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11:8156. Scholar
  37. 37.
    Sugawara M, Ly T, Hershman JM. Medullary thyroid cancer--current treatment strategy, novel therapies, and perspectives for the future. Horm Cancer. 2012;3:218–26. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Nuh Zafer Cantürk
    • 1
  • Sertaç Ata Güler
    • 1
    Email author
  • Turgay Şimşek
    • 1
  1. 1.Division of Breast and Endocrin SurgeryKocaeli UniversityKocaeliTurkey

Personalised recommendations